ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.19
-0.06 (-0.83%)
At close: 4:00PM EDT

7.20 +0.01 (0.14%)
After hours: 5:26PM EDT

Stock chart is not supported by your current browser
Previous Close7.25
Open7.25
Bid7.15 x 1300
Ask7.20 x 2900
Day's Range7.08 - 7.43
52 Week Range5.59 - 15.14
Volume338,440
Avg. Volume627,842
Market Cap126.716M
Beta (3Y Monthly)4.01
PE Ratio (TTM)N/A
EPS (TTM)-3.05
Earnings DateAug 9, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.40
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Zynerba Pharmaceuticals to Present at the 2018 BIO Investor Forum

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Zynerba’s Chief Executive Officer, will present a company overview at the 2018 BIO Investor Forum. A live webcast of the presentation will be accessible on the Investor Relations page of http://www.zynerba.com. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

  • Beverage Giants Buying Into The Cannabis Boom
    Oilprice.com12 days ago

    Beverage Giants Buying Into The Cannabis Boom

    The beverage sector is one of the most profitable in the markets, and now these billion-dollar giants are getting in on the next great North American industry

  • InvestorPlace14 days ago

    2 Marijuana Biotechs to Watch

    On Sept. 27, the United States Drug Enforcement Agency (DEA) made official a long-awaited decision on a cannabidiol (CBD)-based drug. GW Pharmaceuticals’ (NASDAQ:GWPH) drug Epidiolex was reclassified from Schedule 1 to Schedule 5.

  • ACCESSWIRE14 days ago

    The Hottest CBD Stocks

    HENDERSON, NV / ACCESSWIRE / October 1, 2018 / With the DEA rescheduling CBD the top is off, and the time is now to find CBD companies before missing the boat.CBD is a very lucrative business, because ...

  • GlobeNewswire19 days ago

    Zynerba Pharmaceuticals to Present at the Cantor Global Healthcare Conference

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 2018 Cantor Global Healthcare conference. The presentation will take place on October 1, 2018 at 2:55 PM EDT at the InterContinental New York Barclay Hotel. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

  • Benzinga24 days ago

    Cantor Fitzgerald's 7 Buys For 7 Biotechs

    Cantor Fitzgerald has high hopes for patients with rare and orphan diseases.  “We believe that biotech has entered a golden age of innovation and productivity across many therapeutic areas,” the firm said ...

  • Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?
    Zacks25 days ago

    Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?

    Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

  • ACCESSWIRE26 days ago

    CBD Stocks Set to Explode

    HENDERSON, NV / ACCESSWIRE / September 19, 2018 / It's just a matter of time before medical marijuana will become legal in all 50 states. It's not surprising when you consider a recent poll shows 93% of ...

  • What Makes Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) An Attractive Investment?
    Simply Wall St.26 days ago

    What Makes Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) An Attractive Investment?

    I’ve been keeping an eye on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) because I’m attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believeRead More...

  • GlobeNewswirelast month

    Zynerba Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 20th Annual Global Investment Conference sponsored by H.C. Wainwright & Co., L.L.C. on September 5, 2018 at 8:45 AM EDT at the St. Regis New York. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

  • Zynerba Pharmaceuticals Continues Its 3-Day Rally
    InvestorPlace2 months ago

    Zynerba Pharmaceuticals Continues Its 3-Day Rally

    The stock went from its closing price of $6.80 on Tuesday and finished the day off sitting at $8.00. This represents an 17%-increase for Zynerba Pharmaceuticals on Wednesday. Now the rally for ZYNE stock is still going strong on Thursday, Aug. 30, 2018.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ZYNE earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Zynerba Pharmaceuticals Inc Earnings Call

  • The Worst-Performing Marijuana Stocks in July
    Motley Fool2 months ago

    The Worst-Performing Marijuana Stocks in July

    Talk about buzzkills! These five pot stocks all fell by at least 19% last month.

  • Associated Press2 months ago

    Zynerba: 2Q Earnings Snapshot

    On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 89 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire2 months ago

    Zynerba Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights

    DEVON, Pa., Aug. 02, 2018-- Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today ...

  • GlobeNewswire2 months ago

    Zynerba Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Financial Officer, Jim Fickenscher will present a company overview at the 38th Annual Canaccord Genuity Growth Conference on August 8, 2018 at 4:00 PM EDT at the InterContinental Boston. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

  • GlobeNewswire2 months ago

    Zynerba Pharmaceuticals to Host Conference Call to Provide Second Quarter 2018 Business Update

    DEVON, Pa., July 31, 2018-- Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, will host ...

  • ACCESSWIRE3 months ago

    This Unknown Stock Could Trade From $3 to $10 As Wall Street Wakes Up

    CNS disorders are seeing renewed interest from investors, and epilepsy has seen a particular resurgence in investor activity as numerous public companies have found success with new drugs and mechanisms. A little-known company called NeuroOne Medical (NMTC) is making strides with an all-new thin-film electrode technology, which comes from the labs of the Mayo Clinic. This prestigious institute is also a 10% stockholder in newly public NMTC.

  • InvestorPlace3 months ago

    Market Roasts Shares of Zynerba Pharmaceuticals

    Just as shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) were on the way to rebounding back to the $10 level, the stock fell on Friday after the company announced a share issuance. With a 25-percent cut in the ZYNE share price, is the sell-off in this micro-cap biotechnology firm overdone? Zynerba announced a tiny, $32.5 million public offering of its shares: 4.062 million shares at $8 each.

  • Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks
    MarketWatch3 months ago

    Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks

    Valuations today are very high and sentiment is very positive — a bad combination, says Nigam Arora.

  • GlobeNewswire3 months ago

    Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Zynerba Pharmaceuticals, Inc. (ZYNE) today announced the pricing of an underwritten public offering of 4,062,500 shares of its common stock at a price of $8.00 per share, for a gross deal size of $32.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Zynerba has granted the underwriters a 30-day option to purchase up to 609,375 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Cantor Fitzgerald & Co. is acting as the sole book-running manager.

  • Benzinga3 months ago

    Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 19) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Champions Oncology ...

  • GlobeNewswire3 months ago

    Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Zynerba Pharmaceuticals, Inc. (ZYNE) today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  All of the shares to be sold in the offering will be offered by Zynerba.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Zynerba intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. Cantor Fitzgerald & Co. is acting as the sole book-running manager.